Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pituitary Neoplasms 6Acromegaly 5Neuroendocrine Tumors 3Carcinoid Tumor 3Prostatic Neoplasms 2Pituitary ACTH Hypersecretion 2Growth Disorders 2Gigantism 2Gastro-enteropancreatic neuroendocrine tumor 2Serotonin Syndrome 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Nelson Syndrome 1Melanoma 1Lymphoma, Follicular 1Dumping Syndrome 1Carcinoma, Neuroendocrine 1Adrenocortical Hyperfunction 1ACTH Syndrome, Ectopic 1

Interventions

relacorilant 1pembrolizumab 1pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adrenocortical Hyperfunction × pasireotide × Clear all
NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated
68 enrolled 25 charts
Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡